Paper Details

  1. Home
  2. Paper Details

Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.

Author: AgenoWalter, BrekelmansMarjolein P A, BüllerHarry R, ChenCathy Z, CohenAlexander T, GrossoMichael A, MedinaAndria P, MercuriMichele F, RaskobGary E, SegersAnnelise, VanasscheThomas, VerhammePeter, WeitzJeffrey I, WellsPhilip S, WintersShannon M, ZhangGeorge

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This analysis compared the efficacy and safety of edoxaban and warfarin in patients with venous thromboembolism (VTE) considering factors like advanced age, comorbidities, and polypharmacy. The study aimed to address the lack of comparative data for DOACs and warfarin in elderly patients with multiple comorbidities.
Paper Details　
Original Abstract of the Article :
Many patients with venous thromboembolism (VTE) are elderly, have multiple comorbidities and take several concomitant medications. Physicians may prefer warfarin over direct oral anticoagulants (DOACs) in such patients because comparative data are lacking. This analysis was designed to determine the...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.thromres.2017.12.005

データ提供：米国国立医学図書館（NLM）

Navigating the Complex Terrain of VTE: A New Approach to Treatment

The treatment of venous thromboembolism (VTE) is a complex and challenging landscape, like a vast desert with many obstacles. This study investigates the efficacy and safety of edoxaban, a new direct oral anticoagulant (DOAC), in patients with VTE, particularly those with advanced age, multiple comorbidities, and polypharmacy. This research is like a camel caravan, venturing into this complex terrain, seeking to find a safe and effective path to treat this condition.

A Promising Solution: Edoxaban in VTE

The study finds that edoxaban demonstrates comparable efficacy and safety to warfarin in treating VTE, even in patients with advanced age, comorbidities, and polypharmacy. It's like discovering a new oasis in the desert of VTE treatment, offering a promising solution for a complex patient population. This research is like a map, guiding us towards a more individualized approach to VTE treatment, considering the unique needs of each patient.

A Safe and Effective Journey: A Beacon of Hope

This study provides valuable insights into the use of edoxaban in treating VTE, demonstrating its potential as a safe and effective alternative to warfarin, particularly in complex patient populations. It's like a beacon of hope in the desert of VTE treatment, offering a more personalized and patient-centered approach. The authors emphasize the need for continued research to further explore the long-term effects of edoxaban and its potential impact on various patient subgroups.

Dr.Camel's Conclusion

This study represents a significant step forward in the treatment of VTE, particularly for patients with complex health profiles. It highlights the efficacy and safety of edoxaban, offering a promising new option for this challenging condition. This research is like a wellspring of knowledge in the desert of VTE treatment, guiding us towards more effective and personalized care for patients facing this complex health challenge.
Date :
  1. Date Completed 2018-09-12
  2. Date Revised 2018-09-12
Further Info :

Pubmed ID

29248859

DOI: Digital Object Identifier

10.1016/j.thromres.2017.12.005

Related Literature

Article Analysis
・Effects of edoxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.